Claseprubart

Phase 3

Claseprubart is one of 64 therapeutic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Myasthenia Gravis, GeneralizedRecruiting

NeuropathyRecruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Recruiting

Myasthenia Gravis, GeneralizedPhase 3

Recruiting

NeuropathyPhase 2

Recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Vimpat

UCB

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Savella

AbbVie

Phase 3

1 4

Asceniv

CSL Behring

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 7

Claritin

PPerrigo Company

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Neuropathy

NCT06537999

Q4 2030

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT06858579

Q3 2031

Phase 3Recruiting

Myasthenia Gravis, Generalized

NCT07647510

Clinical

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Recruiting·DDianthus Therapeutics·Phase 3·NCT06858579·256 enrolled

Myasthenia Gravis, Generalized1 trial

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)

Recruiting·DDianthus Therapeutics·Phase 3·NCT07647510·195 enrolled

Neuropathy1 trial

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

Recruiting·DDianthus Therapeutics·Phase 2·NCT06537999·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Claseprubart. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Claseprubart. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Dianthus Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDianthus Therapeutics

Claseprubart

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2030

Q3 2031

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Myasthenia Gravis, Generalized1 trial

Neuropathy1 trial

References

Drug Info

Quick Facts

Related News